hepat
c
viru
hcv
small
envelop
positivestrand
rna
viru
classifi
within
famili
flavivirida
genu
hepaciviru
hcv
affect
estim
million
peopl
worldwid
global
health
problem
unlik
rna
virus
usual
caus
acut
diseas
hcv
establish
lifelong
persist
intrahepat
infect
major
infect
individu
lead
frequent
develop
cirrhosi
hepatocellular
carcinoma
current
interferonbas
treatment
regimen
erad
hcv
patient
prevent
hcv
infect
pivot
control
viral
pathogen
hcv
transmit
primarili
via
percutan
exposur
infecti
blood
prior
introduct
antihcv
screen
test
earli
receiv
blood
blood
product
organ
transplant
major
risk
factor
acquir
hcv
infect
current
inject
illicit
drug
repres
major
risk
rout
infect
includ
occup
exposur
needl
stick
sex
mothertoinf
transmiss
except
hivcoinfect
mother
seem
infrequ
interestingli
shown
recent
chimpanze
model
hcv
infecti
plasma
could
surviv
dri
environment
exposur
room
temperatur
least
h
find
rais
possibl
persontoperson
transmiss
hcv
via
bloodcontamin
object
medic
devic
clearli
fundament
quantit
determin
stabil
hcv
environment
condit
evalu
reliabl
procedur
inactiv
viru
howev
effort
hamper
lack
effici
cell
cultur
system
conveni
small
anim
model
hcv
although
hcv
rna
antigen
use
indic
presenc
absenc
viru
particl
detect
method
distinguish
infecti
inactiv
virus
circumv
sever
relat
virus
famili
flavivirida
readili
cultur
vitro
eg
bovin
viral
diarrhoea
viru
bvdv
genu
pestiviru
use
surrog
hcv
studi
inactiv
process
although
model
virus
show
similar
virion
genom
structur
hcv
relev
system
still
need
assess
reliabl
procedur
inactiv
hcv
recent
establish
hcv
cell
cultur
system
base
particular
molecular
clone
offer
opportun
evalu
inactiv
method
hcv
directli
use
cell
line
highli
suscept
hcvcc
infect
stabil
hcvcc
strain
differ
environment
temperatur
room
temperatur
assess
studi
addit
efficaci
sever
commonli
use
viral
inactiv
method
includ
heat
treatment
uvc
light
irradi
aldehydemedi
fixat
deterg
treatment
elimin
hcvcc
infect
evalu
result
reveal
method
abl
inactiv
hcvcc
provid
proper
condit
met
investig
abil
hcvcc
surviv
differ
environment
temperatur
spontan
reduct
viral
titer
rt
determin
individu
hcvcc
stock
ffuml
cultur
medium
lost
infect
incub
h
ffu
assay
becam
neg
residu
infect
found
upon
three
success
passag
inocul
cultur
figur
infect
loss
occur
within
first
h
ffuml
ffuml
reduct
reduct
follow
h
brought
viru
titer
ffuml
close
detect
limit
ffuml
contrast
viral
titer
declin
much
slowli
smoothli
rt
figur
incub
everi
day
led
reduct
viral
titer
day
infect
drop
level
detect
limit
viru
stock
becam
complet
devoid
infect
day
figur
later
data
shown
incub
obviou
loss
viral
infect
detect
within
first
week
figur
howev
notic
nearli
reduct
viral
titer
week
experi
end
lindenbach
et
al
report
infect
hcvcc
chang
three
freezethaw
cycl
consist
found
obviou
reduct
infect
even
five
cycl
freez
thaw
hcvcc
stock
data
shown
suggest
hcvcc
rel
insensit
freezethaw
manipul
determin
whether
presenc
human
blood
affect
stabil
hcvcc
concentr
hcvcc
stock
dilut
normal
human
serum
achiev
titer
ffuml
rt
hcvcccontain
serum
found
gradual
loos
infect
week
log
reduct
viral
titer
everi
week
incub
figur
howev
hcvcc
dilut
human
serum
ffuml
dri
surfac
cell
cultur
dish
incub
rt
week
infect
detect
upon
inocul
reconstitut
serum
onto
cell
even
three
consecut
cell
passag
data
shown
aggreg
result
suggest
hcvcc
abl
surviv
ambient
condit
especi
liquid
environ
stabil
hcvcc
invers
correl
temperatur
evalu
sensit
hcvcc
heat
treatment
aliquot
hcvcc
stock
ffuml
treat
three
increas
temperatur
respect
shown
figur
hcvcc
lost
infect
within
min
reduct
viral
titer
ffuml
ffuml
howev
min
small
amount
infecti
viru
still
detect
ffuml
complet
viral
inactiv
took
place
min
figur
residu
infect
detect
sampl
treat
beyond
time
point
data
shown
heat
treatment
higher
temperatur
led
rapid
declin
viral
titer
figur
hcv
stock
inactiv
complet
min
respect
similar
kinet
viral
inactiv
observ
heat
treatment
perform
hcvcc
stock
spike
human
serum
incub
viral
titer
drop
first
min
ffuml
ffuml
min
viral
infect
could
longer
detect
figur
hcvcccontain
serum
complet
inactiv
min
respect
figur
taken
togeth
result
indic
hcvcc
sensit
heat
treatment
higher
temperatur
could
use
effect
hcvcc
inactiv
note
presenc
human
serum
seem
affect
suscept
hcvcc
heat
treatment
examin
effect
continu
uvc
light
hcvcc
infect
aliquot
hcvcc
stock
ffuml
place
plate
subject
uvc
light
irradi
differ
time
point
residu
titer
determin
immedi
shown
figur
viral
titer
declin
rapidli
follow
uvc
irradi
first
sec
exposur
respect
sec
viral
titer
decreas
level
ffuml
close
detect
limit
ffu
assay
hcvcc
infect
elimin
complet
min
irradi
contrast
control
nonirradi
sampl
incub
rt
min
show
loss
titer
data
shown
effect
uvc
light
infect
hcvcc
spike
human
serum
also
investig
shown
figur
decreas
viral
infect
observ
first
sec
irradi
ffuml
ffuml
exposur
uvc
light
sec
brought
viral
titer
level
close
limit
detect
addit
exposur
total
sec
complet
elimin
residu
infect
figur
given
radiant
intens
distanc
cm
uvc
lamp
jsec
data
suggest
continu
uvc
light
radiat
dose
sec
suffici
inactiv
hcvcc
titer
ffuml
mtt
assay
first
carri
determin
aldehyd
concentr
longer
affect
cell
viabil
found
formaldehyd
glutaraldehyd
longer
demonstr
effect
cell
growthviabl
figur
also
aldehyd
concentr
viral
titrat
result
perturb
tabl
therefor
viral
sampl
treat
formaldehyd
glutaraldehyd
dilut
infect
assay
reduct
viral
titer
hcvcc
stock
ffuml
follow
exposur
aldehyd
summar
tabl
h
posttreat
formaldehyd
singl
fluoresc
focu
detect
one
triplic
well
ffu
assay
two
well
show
neg
result
viru
sampl
treat
h
neg
ffu
assay
howev
posit
ifa
result
observ
second
cell
passag
indic
presenc
residu
infecti
viru
h
treatment
residu
infect
could
detect
third
cell
passag
tabl
compar
formaldehyd
glutaraldehyd
exhibit
higher
efficaci
viral
inactiv
ten
minut
glutaraldehyd
treatment
result
reduct
infect
min
viru
stock
inactiv
complet
residu
infect
detect
third
cell
passag
tabl
effect
aldehyd
infect
hcvcc
human
serum
ffuml
also
evalu
use
procedur
describ
shown
tabl
hour
incub
formaldehyd
decreas
viral
titer
limit
detect
ffuml
drop
hour
residu
infect
could
detect
tabl
agreement
result
hcvcc
cultur
medium
glutaraldehyd
also
effect
formaldehyd
inactiv
hcvcc
human
serum
result
ffu
assay
becam
neg
treatment
glutaraldehyd
min
although
small
amount
infecti
viru
detect
second
cell
passag
min
residu
infect
could
detect
third
cell
passag
indic
effect
viral
inactiv
achiev
tabl
experi
control
pbstreat
sampl
show
obviou
loss
infect
titrat
presenc
formaldehyd
glutaraldehyd
data
shown
result
suggest
aldehyd
abl
inactiv
hcvcc
regardless
presenc
human
serum
hcvcc
stock
glutaraldehyd
effect
formaldehyd
determin
deterg
concentr
longer
cytotox
cell
cell
treat
individu
serial
dilut
deterg
subject
mtt
assay
assess
cell
viabil
base
mtt
assay
result
figur
hcvcc
stock
ffuml
spike
human
serum
ffuml
treat
sd
triton
test
infect
either
sdstreat
sampl
triton
sampl
dilut
summar
tabl
detergenttr
sampl
neg
ffu
assay
demonstr
residu
infect
upon
three
consecut
passag
inocul
cell
tabl
contrast
control
sampl
treat
deterg
show
obviou
loss
viru
titer
effect
deterg
disrupt
intracellular
hcvcc
virion
also
evalu
cultur
cell
posit
determin
immunofluoresc
assay
lyse
deterg
solut
sd
triton
pb
respect
clarifi
supernat
test
infect
cell
sdslyse
sampl
triton
sampl
dilut
respect
infect
detect
cell
lysat
three
consecut
passag
inocul
cell
tabl
control
cell
lysat
prepar
freez
thaw
absenc
deterg
retain
high
infect
tabl
taken
collect
result
suggest
deterg
test
concentr
highli
effect
elimin
infect
extracellular
intracellular
hcvcc
particl
studi
detail
analysi
conduct
stabil
hcvcc
variou
environment
temperatur
also
evalu
efficaci
sever
convent
viral
inactiv
procedur
elimin
hcvcc
infect
shown
previous
genotyp
hcv
infecti
plasma
could
surviv
dri
environment
exposur
rt
least
h
result
current
studi
demonstr
viru
genotyp
grown
cell
cultur
surviv
rt
day
respect
figur
note
stabil
hcvcc
spike
human
serum
differ
much
cell
cultur
medium
incub
rt
fig
store
viru
found
rel
stabl
without
drastic
loss
titer
observ
period
figur
latter
result
agreement
previou
report
deal
chimer
viru
abil
hcvcc
surviv
variou
environment
temperatur
warrant
precaut
handl
dispos
object
materi
may
contamin
hcv
minim
risk
hcv
transmiss
heat
treatment
wide
use
viral
inactiv
method
effect
envelop
nonenvelop
virus
mechan
heatmedi
inactiv
includ
denatur
viral
protein
well
disassembl
viru
particl
noninfecti
viral
subunit
singl
protein
virus
hcv
famili
flavivirida
shown
sensit
heat
treatment
yellow
fever
viru
routin
inactiv
min
bvdv
yellow
fever
viru
report
inactiv
effect
min
respect
current
studi
similar
kinet
viral
inactiv
follow
heat
treatment
observ
hcvcc
cultur
medium
human
serum
min
min
suffici
elimin
infect
hcvcc
incub
min
requir
achiev
complet
viral
inactiv
figur
therefor
pretreat
hcv
posit
sera
min
may
absolut
reliabl
elimin
infect
howev
effici
heat
treatment
could
affect
varieti
factor
initi
viral
titer
protein
concentr
viru
suspens
well
exist
viral
aggreg
exact
temperatur
time
requir
reliabl
hcv
inactiv
evalu
specif
condit
uv
light
irradi
anoth
commonli
use
physic
method
viral
inactiv
uvc
wavelength
rang
nm
prevent
viral
replic
induc
format
pyrimidin
dimer
viral
genom
recent
studi
report
bvdv
suspend
pb
could
inactiv
complet
uvc
light
viral
suspens
contain
fb
requir
higher
radiat
dose
current
studi
demonstr
hcvcc
cultur
medium
ffuml
volum
depth
cm
could
inactiv
complet
uvc
irradi
dose
within
min
figur
spike
human
serum
ffuml
requir
irradi
dose
full
inactiv
figur
therefor
uvc
light
irradi
repres
highli
effect
mean
inactiv
hcvcc
effici
affect
human
serum
compon
may
interact
hcv
viron
vivo
howev
irradi
dose
requir
specif
occas
may
depend
sampl
volum
initi
viral
titer
chemic
crosslink
reagent
formaldehyd
inactiv
virus
primarili
denatur
viral
protein
well
nucleic
acid
immunogen
viral
particl
retain
inactiv
formalin
formaldehyd
treatment
use
techniqu
prepar
inactiv
viru
vaccin
tissu
fixat
histolog
immunohistochemistri
formalin
paraformaldehyd
routin
use
glutaraldehyd
anoth
effect
protein
crosslink
reagent
mostli
use
fixat
tissu
electron
microscopi
although
detail
mechan
entir
clear
yet
success
inactiv
mani
virus
glutaraldehyd
includ
hepat
b
viru
human
immunodefici
viru
hiv
sar
coronaviru
report
demonstr
rt
h
exposur
formaldehyd
min
exposur
glutaraldehyd
respect
could
reduc
hcvcc
infect
ffuml
undetect
level
tabl
concentr
aldehyd
also
effect
inactiv
hcvcc
presenc
human
serum
tabl
slightli
longer
time
requir
h
formaldehyd
treat
sampl
min
glutaraldehyd
treat
sampl
respect
like
attribut
higher
initi
titer
hcvcc
stock
test
ffuml
howev
limit
current
studi
cytotox
effect
aldehyd
infect
viral
sampl
could
analyz
dilut
may
somehow
reduc
sensit
assay
note
howev
routin
use
concentr
aldehyd
fixat
purpos
formaldehyd
glutaraldehyd
far
excess
one
examin
current
studi
therefor
highli
effici
achiev
hcv
inactiv
deterg
highli
effici
disrupt
lipidenvelop
virus
solventdeterg
sd
treatment
standard
method
inactiv
virus
present
human
blood
product
effect
ionic
sd
nonion
triton
deterg
hcvcc
infect
investig
three
deterg
test
concentr
reduc
hcvcc
infect
rapidli
undetect
level
tabl
importantli
intracellular
hcvcc
releas
cultur
fluid
could
inactiv
deterg
regardless
presenc
human
serum
indic
compon
cultur
medium
human
serum
intracellular
protein
interfer
disrupt
process
exert
deterg
current
experiment
condit
effect
hcvcc
inactiv
took
place
immedi
vortexmix
render
imposs
delin
kinet
viral
infect
reduct
deterg
treatment
process
find
reminisc
report
hiv
previou
studi
demonstr
spike
solut
contain
triton
inactiv
complet
within
min
case
aldehydeinactiv
experi
cytotox
effect
deterg
limit
sensit
current
assay
interestingli
although
triton
detect
effect
cell
viabil
figur
still
lower
hcvcc
infect
latter
compar
determin
presenc
sd
without
deterg
tabl
like
residu
triton
still
disrupt
effect
virion
integr
import
viral
infect
altern
deterg
may
caus
cell
surfac
alter
extrem
low
concentr
affect
process
hcvcc
entri
howev
maintain
sensit
assay
detergenttr
sampl
dilut
infect
test
collect
robust
immedi
action
deterg
destroy
hcvcc
infect
support
use
sd
treatment
procedur
elimin
potenti
hcv
contamin
blood
product
summari
result
present
current
studi
reveal
stabil
hcvcc
genotyp
strain
differ
temperatur
provid
quantit
evid
heat
uvc
light
irradi
aldehyd
formaldehyd
glutaraldehyd
deterg
treatment
use
effect
mean
inactiv
hcvcc
howev
stabil
resist
hcv
differ
inactiv
method
may
vari
genotyp
genotyp
even
strain
strain
optim
method
procedur
use
hcv
inactiv
verifi
particular
circumst
also
note
result
current
studi
develop
use
vitro
cell
cultur
system
base
hepatoma
cell
may
differ
normal
human
hepatocyt
support
hcv
infect
thu
extent
procedur
describ
herein
appli
vivo
set
await
evalu
cell
line
gener
gift
dr
takaji
wakita
cell
clone
stabli
express
human
use
throughout
experi
cell
line
chosen
found
approxim
sensit
titrat
hcvcc
infect
cell
line
data
shown
cell
maintain
dmem
supplement
fetal
bovin
serum
invitrogen
mm
hepe
invitrogen
merck
germani
gener
viru
stock
cell
cultur
supernat
collect
fulllength
rnatransfect
cell
kindli
provid
dr
takaji
wakita
use
infect
cell
grown
flask
multipl
infect
moi
infect
cell
passag
interv
split
ratio
progress
larger
cultur
vessel
day
postinfect
cultur
supernat
harvest
clarifi
centrifug
min
rpm
store
aliquot
hcvcc
stock
infecti
titer
viru
stock
determin
focusform
unit
ffu
assay
describ
immedi
infecti
titer
unconcentr
viru
stock
use
either
ffuml
ffuml
current
studi
specifi
experi
determin
stabil
hcvcc
suscept
individu
inactiv
method
presenc
human
serum
condit
better
mimic
circul
hcv
virion
vivo
hcvcc
stock
first
concentr
use
amicon
devic
nmwl
membran
millipor
describ
previous
concentr
viru
stock
ffuml
dilut
normal
human
serum
heatinactiv
achiev
infecti
titer
ffuml
human
serum
contain
hcvcc
store
aliquot
use
infecti
titer
viru
stock
treat
viral
sampl
determin
ffu
assay
describ
previous
use
indirect
immunofluoresc
assay
ifa
hcv
brief
serial
dilut
sampl
dilut
factor
gener
rang
inocul
onto
cell
seed
plate
day
infect
cellswel
h
incub
cell
refe
fresh
medium
follow
addit
h
cell
fix
paraformaldehyd
min
room
temperatur
rt
block
min
block
buffer
bsa
triton
fb
pb
follow
incub
polyclon
antibodi
hcv
kindli
provid
dr
takaji
wakita
dilut
h
incub
rt
cell
wash
extens
pb
incub
fitcconjug
goat
antirabbit
igg
beij
zhongshanjinqiao
china
dilut
h
follow
pb
wash
number
fluoresc
foci
focu
defin
cluster
infect
cell
immunostain
posit
antigen
per
well
appropri
dilut
gener
contain
foci
per
well
count
infecti
titer
express
ffuml
calcul
averag
foci
number
triplic
duplic
sampl
deriv
human
serum
spike
hcvcc
well
detect
limit
ffu
assay
ffuml
sampl
infecti
titer
detect
limit
assay
potenti
residu
infect
examin
follow
cell
seed
plate
inocul
sampl
test
inocul
cell
passag
interv
one
well
three
well
passag
split
ratio
allow
growth
residu
infecti
viru
ifa
perform
cell
passag
ifa
result
remain
neg
three
success
cell
passag
day
postinocul
test
sampl
consid
inactiv
complet
hcvcc
stock
titer
ffuml
dispens
aliquot
tightli
cap
microcentrifug
tube
incub
rt
respect
protect
light
aliquot
incub
remov
everi
h
incub
rt
remov
everi
day
everi
week
respect
store
viru
titrat
cell
viral
stabil
assay
hcvcc
spike
normal
human
serum
ffuml
aliquot
incub
rt
remov
everi
day
titrat
time
point
select
experi
design
base
result
sever
pilot
experi
hcvcc
stock
cultur
medium
ffuml
concentr
hcvcc
stock
dilut
human
serum
ffuml
dispens
aliquot
tightli
cap
microcentrifug
tube
incub
water
bath
temperatur
respect
design
time
point
aliquot
remov
transfer
immedi
icewat
bath
stop
effect
heat
subject
ffu
assay
viru
titrat
two
hundredmicrolit
aliquot
hcvcc
stock
ffuml
hcvcc
dilut
normal
human
serum
ffuml
place
plate
give
volum
depth
cm
expos
continu
uvc
light
cm
beneath
longitudin
midpoint
uvc
lamp
model
wavelength
nm
beij
haidian
konghou
high
temperatur
composit
materi
factori
china
distanc
cm
radiant
intens
uvc
lamp
jsec
specifi
manufactur
vari
length
exposur
sampl
remov
residu
infect
titrat
cell
immedi
control
sampl
set
parallel
incub
time
period
protect
uvc
light
mtt
tetrazolium
bromid
cytotox
assay
carri
determin
concentr
aldehyd
deterg
longer
cytotox
cell
solut
aldehyd
formaldehyd
glutaraldehyd
deterg
sodium
dodecyl
sulfat
sd
triton
nonidet
dilut
serial
cell
cultur
medium
respect
rang
concentr
reagent
design
base
result
pilot
experi
dilut
reagent
ad
cell
seed
plate
cellswel
day
h
incub
treat
cell
refe
fresh
cultur
medium
keep
exposur
time
individu
reagent
hcv
infect
assay
follow
addit
h
mtt
solut
mgml
sigmaaldrich
ad
well
incub
mtt
solut
remov
replac
dimethyl
sulfoxid
dmso
sigmaaldrich
per
well
formazan
crystal
dissolv
agit
min
rt
absorb
solut
well
measur
nm
use
enzymelink
immunosorb
assay
plate
reader
biorad
percentag
cell
viabil
calcul
ratio
absorb
treat
cell
compar
untreat
control
experi
perform
triplic
repeat
twice
formaldehyd
glutaraldehyd
solut
beij
chemic
reagent
compani
china
dilut
pb
formaldehyd
glutaraldehyd
respect
ad
viral
sampl
hcvcc
stock
cell
cultur
medium
ffuml
hcvcccontain
human
serum
ffuml
achiev
final
concentr
formaldehyd
glutaraldehyd
respect
differ
time
period
rt
treat
sampl
dilut
cultur
medium
immedi
stop
inactiv
reaction
well
elimin
cytotox
effect
aldehyd
subsequ
ffu
assay
accord
result
mtt
assay
presenc
formaldehyd
glutaraldehyd
appreci
effect
viabil
cell
immedi
dilut
hcv
infect
sampl
titrat
ffu
assay
cell
sampl
show
neg
result
ffu
assay
subject
residu
infect
test
describ
hcv
infect
assay
control
pb
substitut
aldehyd
treat
viru
stock
dilut
infect
cell
presenc
either
formaldehyd
glutaraldehyd
respect
solut
sd
wv
triton
vv
vv
prepar
pb
ad
aliquot
viral
sampl
hcvcc
stock
cell
cultur
medium
ffuml
normal
human
serum
contain
hcvcc
ffuml
achiev
final
concentr
either
sd
triton
gentl
mix
within
min
treat
sampl
dilut
sdstreat
sampl
triton
sampl
immedi
cultur
medium
negat
cytotox
effect
deterg
base
mtt
assay
result
presenc
sd
triton
demonstr
effect
viabil
cell
subject
ffu
assay
sampl
neg
ffu
assay
result
examin
residu
infect
control
pb
use
place
deterg
treat
viru
stock
subsequ
dilut
either
infect
cell
presenc
sd
triton
respect
assess
abil
deterg
disrupt
intracellular
hcv
infect
cell
monolay
grown
plate
approxim
cell
stain
posit
time
cell
lysi
examin
ifa
detach
trypsinedta
wash
extens
pb
cell
pellet
resuspend
pb
contain
sd
triton
respect
deterg
disrupt
cell
concentr
visual
microscopi
centrifug
supernat
cell
lysat
dilut
sdslyse
sampl
triton
sampl
cultur
medium
infect
assay
ifa
hcv
perform
inocul
cell
three
consecut
cell
passag
control
infect
cell
wash
extens
pb
pellet
resuspend
pb
lyse
three
cycl
freez
thaw
infect
supernat
titrat
cell
author
declar
compet
interest
hz
kl
conceiv
studi
design
experi
hss
jl
ss
ly
carri
experiment
work
hss
hz
kl
wrote
paper
author
read
approv
final
manuscript
